About the Company
We do not have any company description for Maze Therapeutics, Inc. at the moment.
Exchange
Nasdaq
Fundamental Data and Insider Transactions (Quarterly data) Full Screen
Loading the fundamentals chart...
Latest News on Maze Therapeutics, Inc.
Shionogi & Co., Ltd. and Maze Therapeutics, Inc. Announce Exclusive ...
Shionogi & Co., Ltd. and Maze Therapeutics, Inc. Announce Exclusive Worldwide License Agreement for MZE001, a Novel Therapeutic Candidate for the Treatment of Pompe Disease ...
Maze Therapeutics Reports Second Quarter 2025 Financial Results and Recent Highlights
MZE782 Phase 1 Trial in Healthy Volunteers to Provide Proof of Mechanism Data for Phenylketonuria (PKU) and Chronic Kidney ...
Maze Therapeutics Announces Pricing of Upsized Initial Public Offering
Investors: Jillian Connell, Maze Therapeutics jconnell@mazetx.com (650) 850-5080 Media: Dan Budwick, 1AB dan@1abmedia.com Source: Maze Therapeutics, Inc. 2025 GlobeNewswire, Inc.
Maze Therapeutics Inc. (MAZE) Stock Price Today - WSJ
View the latest Maze Therapeutics Inc. (MAZE) stock price, news, historical charts, analyst ratings and financial information from WSJ.
Maze Therapeutics Reports Fourth Quarter and Full-Year 2024 Financial ...
MZE829 Phase 2 HORIZON Trial Enrolling Patients with APOL1 Kidney Disease (AKD); Initial Data Expected in Q1 2026 MZE782 Phase 1 Healthy Volunteer Trial Ongoing; Initial Data Expected in H2 2025 ...
Maze Therapeutics Prices IPO At $16/Shr - Nasdaq
(RTTNews) - Maze Therapeutics, Inc., (MAZE), a clinical-stage biopharmaceutical company focused on developing small molecule precision medicines, has priced its initial public offering or IPO of 8 ...
Maze Therapeutics CEO to Present Company Overview at 3rd ... - Nasdaq
Maze Therapeutics, Inc., a biopharmaceutical company focused on developing precision medicines for renal, metabolic, and cardiovascular diseases, announced that CEO Jason Coloma, Ph.D., will ...
Maze Therapeutics to Participate in the Jefferies 2025 Global ...
SOUTH SAN FRANCISCO, Calif., May 29, 2025 (GLOBE NEWSWIRE) -- Maze Therapeutics, Inc. (Nasdaq: MAZE), a clinical-stage biopharmaceutical company developing small molecule precision medicines for ...
Maze Therapeutics, Inc.
Maze Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in harnessing the power of human genetics to develop novel, small molecule precision medicines for patients ...
Maze Therapeutics Reports Fourth Quarter and Full-Year ... - Morningstar
SOUTH SAN FRANCISCO, Calif., March 31, 2025 (GLOBE NEWSWIRE) -- Maze Therapeutics, Inc. (Nasdaq: MAZE), a clinical-stage biopharmaceutical company developing small molecule precision medicines for ...
Similar Companies
Loading the latest forecasts...